Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06150417

MDRT in Prostate Cancer Treated With Long-term Androgen Deprivation Therapy in the STAMPEDE Trial (METANOVA)

The purpose of this study is to find out if giving radiation therapy (RT) to areas of metastatic prostate cancer at the time a participant is diagnosed will help control disease better than the usual treatment. This treatment is called metastasis-directed radiotherapy (MDRT).

The usual treatment for prostate cancer that has spread to other parts of the body is to give lifelong treatment with hormone therapy (also known as androgen deprivation therapy or ADT). Participants may also be given prostate RT even if the disease is metastatic. Participants will receive hormone therapy (the standard treatment for prostate cancer) for 12 months. The hormone therapy agents may be taken by mouth or given as an injection. Participants will also have prostate RT. Up to 50 participants will have surgery to remove the prostate instead of having prostate RT. A portion of the participants will be randomized to receive MDRT to areas where the cancer has spread. For participants who have surgery to remove their prostate, they will be asked to allow tissue samples collected during the surgery to be sent to an outside lab for research tests and extra blood samples drawn for research tests before starting the study, and at the time the cancer becomes worse if applicable. Participation in the study will last approximately 12 months, and will be followed by their doctor for up to five years per standard of care.

The main goal is to compare the efficacy of the standard of care (standard systemic therapy + definitive prostate-directed local therapy) versus the standard of care with metastasis-directed radiotherapy (MDRT) for consolidation of metastatic disease.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Prostate Cancer Genital Diseases Genital Diseases, Male Genital Neoplasms, Male Male Urogenital Diseases Malignant Neoplasm of Prostate Neoplasms Neoplasms by Site Prostatic Diseases Prostatic Neoplasms Secondary Malignant Neoplasm of Prostate Urogenital Diseases Urogenital Neoplasms

Age range

18 year and older

Sex eligibility

Male

Study type

Interventional

Phase

Phase 2

Primary location

University Hospitals Cleveland Medical Center Seidman Cancer Center, Cleveland, Ohio, United States

Loading trial locations.

About this study

Prostate cancer (PCa) is the most common cancer in men worldwide, with 10% diagnosed with metastatic disease at the time of presentation. The metastatic capacity of cancers behaves along a spectrum of disease progression, such that some solid tumors have spread widely before clinical detectability and others never metastasize. While metastatic disease has historically been treated with palliative intent, an oligometastatic state where metastases are limited in number and location has emerged in which participants with oligometastatic disease may benefit from effective local therapy in addition to systemic therapy. Systemic standard-of-care therapies often include androgen deprivation therapy (ADT) and Androgen receptor signaling inhibitor (ARSI). Studies have shown that administering local radiotherapy (RT) to the prostate in addition to standard of care may improve radiographic profession-free survival. It may be even more efficacious to add metastasis-directed radiotherapy (MDRT) to the treatment of oligometastatic prostate cancer cases. More research is necessary to investigate the application of MDRT to improve disease control.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Participant must be ≥ 18 years of age.
  • Participant must have an ECOG performance status ≤ 1.
  • Histologic confirmation of prostate adenocarcinoma of the prostate gland, with evidence of metastasis on imaging by conventional imaging (MRI, CT, or 99mTc bone scan) or PSMA PET/CT. Biopsy of sites of metastasis is strongly encouraged, but not required.
  • There must be at least 10-15 unstained slides from 2 cores of the highest tumor cellularity available.
  • Newly diagnosed disease with no prior treatment(surgery, radiation or systemic treatment, ie hormone therapy or chemotherapy) to the primary disease.
  • Participants may have started LHRH agonist or antagonist therapy, and/or androgen receptor signaling inhibitor (ARSI) as long as it was not started more than 30 days before the participant is enrolled on this study.
  • In participants who undergo only conventional imaging, oligometastatic disease is defined as 1-5 discrete metastatic sites in the bone and/or extra-pelvic lymph node (LN) stations.
  • Extra-pelvic LN stations are superior to the regional/pelvic LN stations. Pelvic LN stations commence at the bifurcation of the aorta and bifurcation of the proximal inferior vena cava to the common iliac veins.
  • Radiographic criteria for a LN to be considered a metastatic focus is defined as short-axis diameter in the axial plane of ≥ 1.0 cm, with irregular border and/or heterogeneous morphology
  • In participants who undergo PSMA PET/CT (in the presence or absence of conventional imaging), oligometastatic disease is defined as 1-10 PSMA avid bone lesions and/or extra-pelvic LN stations. The MI-RADS reporting system will be followed to guide PSMA PET interpretation
  • In participants extra-pelvic nodal (M1a) disease only by PSMA PET/CT and M0 by conventional imaging (i.e. extra-pelvic LN did not meet size criteria by CT), participant must meet 2 of 3 following criteria in order to be eligible:
  • 1. PSA ≥ 40
  • 2. Evidence of cN1 disease (pelvic LN)
  • 3. Decipher score ≥ 0.89
  • Adequate organ and marrow function to receive treatment per treating physician
  • Medically fit for treatment and agreeable to follow-up.
  • Ability to understand and the willingness to sign a written informed consent.

Exclusion criteria

Participants with the presence of any of the following:

  • Castration resistant prostate cancer (CRPC).
  • Evidence of visceral or intracranial metastases.
  • Participant receiving any other investigational agents for cancer.
  • Participant is participating in a concurrent treatment protocol for cancer.
  • Unable to lie flat during or tolerate PET/MRI, PET/CT or SBRT.
  • Prior definitive treatment to the primary prostate cancer or pelvis.
  • Participant with uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, uncontrolled diabetes (HgA1c > 10), active pituitary or adrenal dysfunction, or psychiatric illness/social situations that would limit compliance with study requirements
  • History of another active malignancy within the previous 2 years, except for non-melanoma skin cancer, non-muscle invasive bladder cancer, or a malignancy that is considered cured with minimal risk of recurrence
  • Active Crohn's disease or ulcerative colitis despite medical management.
  • Refusal to sign informed consent.
  • Any condition that in the opinion of the investigator would preclude participation in this study

Treatment and study plan

Androgen deprivation therapy (ADT)

Drug

Standard androgen deprivation therapy (ADT) will be administered at the discretion of treating physician.

Androgen receptor signaling inhibitor (ARSI)

Drug

Standard androgen receptor signaling inhibitors (ARSI) will be administered at the discretion of the treating physician.

Local Therapy: Radical Prostatectomy (RP) or Radiotherapy (RT)

Other

Local therapy will either be radiotherapy (RT) or radical prostatectomy (RP).

  • Prostate +/- pelvic nodal radiation
  • Radical prostatectomy + pelvic lymph node dissection

Metastasis directed radiotherapy (MDRT)

Radiation

In participants randomized to the MDRT arm, MDRT to all lesions will be performed by the end of Week 24. Selection of a particular regimen (the dose and fractionation) will based on the size and location of the participant's metastatic site and the surrounding normal tissue constraints.

Primary outcomes

  1. Failure-free survival (FFS)

    Time frame: Up to 5 years from treatment

    Failure-free survival, defined as time from randomization to first evidence of at least one of: biochemical failure; progression either locally in lymph nodes, or in distant metastases; skeletal related event (where confirmed disease progression);any salvage intervention (local or systemic) required after 12m of planned SOC therapy; or death from prostate cancer.

    Biochemical failure, based on the PSA nadir in the first 24 weeks after randomization, is defined as at least one of:

    post-RT:

    • as per the Prostate Cancer Clinical Trials Working Group 3 (PCWG3), where PSA must rise by ≥ 25% and ≥ 2ng/mL above nadir, confirmed by progression at two time points at least 3 weeks apart
    • post-RP: serum PSA nadir + 0.4 ng/mL, requiring confirmation ≥4 weeks later

Secondary outcomes

  1. Overall survival (OS)

    Time frame: Up to 5 years from treatment

    Overall Survival (OS) is defined as the time from randomization until death due to any cause. For participants who survive, time to death will be censored at the time of last contact. The distributions of OS for each treatment arm will be plotted using the Kaplan-Meier method, and median values for each will be estimated and reported with 95% CIs for each treatment arm and compared using stratified log-rank tests. Univariable Cox proportional hazard models will be used to estimate the effect of MDRT on OS.

  2. Radiographic progression-free survival (rPFS)

    Time frame: Up to 5 years from treatment

    Radiographic progression-free survival (rPFS) is defined as the time from randomization until clinical progression, detection of at least one new metastatic lesion on CT, MRI, bone scan or Prostate Specific Membrane Antigen (PSMA) PET, or death from prostate cancer. The distributions of rPFS for each treatment arm will be plotted using the Kaplan-Meier method, and median values for each will be estimated and reported with 95% CIs for each treatment arm and compared using stratified log-rank tests. Univariable Cox proportional hazard models will be used to estimate the effect of MDRT on rPFS.

  3. Time-to-next-intervention (TTNI)

    Time frame: Up to 5 years from treatment

    TTNI is defined as time-to-next-intervention. TTNI will be summarized in each arm and compared using Chi-square tests, as well as time-to-event analyses using cumulative incidence methods.

  4. Time-to-castration-resistant prostate cancer

    Time frame: Up to 5 years from treatment

    The rate of time-to-castration-resistant prostate cancer will be summarized in each arm and compared using Chi-square tests, as well as time-to-event analyses using cumulative incidence methods.

  5. Prostate-specific cancer mortality (PCSM)

    Time frame: Up to 5 years from treatment

    Prostate cancer specific mortality (PCSM) is defined the time from randomization to death directly attributable to prostate cancer, death from treatment complications, or death from unknown causes in participants with active prostate cancer or previously documented clinical or biochemical relapse.

  6. Change in EPIC-26 Sexual Domain Score

    Time frame: Baseline, 1 year after treatment

    EPIC-26 is the validated short version of "The Expanded Prostate Cancer Index Composite". EPIC-26 will be administered as a health related quality of life questionnaire for participants with prostate cancer. EPIC-26 consists of 26 items under 5 domains. This study will analyze 4 of the domains, including the urinary, bowel, sexual, and hormonal domain. Each domain will be scaled, scored, and compared by arm.

    EPIC-26 assess participant function and bother on a qualitative scale which is then normalized on a scale of 0 to 100 (worst to best) to calculate individual domain scores.

  7. Change in EPIC-26 Sexual Domain Score

    Time frame: Baseline, 3 years after treatment

    EPIC-26 is the validated short version of "The Expanded Prostate Cancer Index Composite". EPIC-26 will be administered as a health related quality of life questionnaire for participants with prostate cancer. EPIC-26 consists of 26 items under 5 domains. This study will analyze 4 of the domains, including the urinary, bowel, sexual, and hormonal domain. Each domain will be scaled, scored, and compared by arm.

    EPIC-26 assess participant function and bother on a qualitative scale which is then normalized on a scale of 0 to 100 (worst to best) to calculate individual domain scores.

  8. Change in EPIC-26 Urinary Domain Score

    Time frame: Baseline, 1 year after treatment

    EPIC-26 is the validated short version of "The Expanded Prostate Cancer Index Composite". EPIC-26 will be administered as a health related quality of life questionnaire for participants with prostate cancer. EPIC-26 consists of 26 items under 5 domains. This study will analyze 4 of the domains, including the urinary, bowel, sexual, and hormonal domain. Each domain will be scaled, scored, and compared by arm.

    EPIC-26 assess participant function and bother on a qualitative scale which is then normalized on a scale of 0 to 100 (worst to best) to calculate individual domain scores.

  9. Change in EPIC-26 Urinary Domain Score

    Time frame: Baseline, 3 years after treatment

    EPIC-26 is the validated short version of "The Expanded Prostate Cancer Index Composite". EPIC-26 will be administered as a health related quality of life questionnaire for participants with prostate cancer. EPIC-26 consists of 26 items under 5 domains. This study will analyze 4 of the domains, including the urinary, bowel, sexual, and hormonal domain. Each domain will be scaled, scored, and compared by arm.

    EPIC-26 assess participant function and bother on a qualitative scale which is then normalized on a scale of 0 to 100 (worst to best) to calculate individual domain scores.

  10. Change in EPIC-26 Hormone Domain Score

    Time frame: Baseline, 1 year after treatment

    EPIC-26 is the validated short version of "The Expanded Prostate Cancer Index Composite". EPIC-26 will be administered as a health related quality of life questionnaire for participants with prostate cancer. EPIC-26 consists of 26 items under 5 domains. This study will analyze 4 of the domains, including the urinary, bowel, sexual, and hormonal domain. Each domain will be scaled, scored, and compared by arm.

    EPIC-26 assess participant function and bother on a qualitative scale which is then normalized on a scale of 0 to 100 (worst to best) to calculate individual domain scores.

  11. Change in EPIC-26 Hormone Domain Score

    Time frame: Baseline, 3 years after treatment

    EPIC-26 is the validated short version of "The Expanded Prostate Cancer Index Composite". EPIC-26 will be administered as a health related quality of life questionnaire for participants with prostate cancer. EPIC-26 consists of 26 items under 5 domains. This study will analyze 4 of the domains, including the urinary, bowel, sexual, and hormonal domain. Each domain will be scaled, scored, and compared by arm.

    EPIC-26 assess participant function and bother on a qualitative scale which is then normalized on a scale of 0 to 100 (worst to best) to calculate individual domain scores.

  12. Change in EPIC-26 Bowel Domain Score

    Time frame: Baseline, 1 year after treatment

    EPIC-26 is the validated short version of "The Expanded Prostate Cancer Index Composite". EPIC-26 will be administered as a health related quality of life questionnaire for participants with prostate cancer. EPIC-26 consists of 26 items under 5 domains. This study will analyze 4 of the domains, including the urinary, bowel, sexual, and hormonal domain. Each domain will be scaled, scored, and compared by arm.

    EPIC-26 assess participant function and bother on a qualitative scale which is then normalized on a scale of 0 to 100 (worst to best) to calculate individual domain scores.

  13. Change in EPIC-26 Bowel Domain Score

    Time frame: Baseline, 3 years after treatment

    EPIC-26 is the validated short version of "The Expanded Prostate Cancer Index Composite". EPIC-26 will be administered as a health related quality of life questionnaire for participants with prostate cancer. EPIC-26 consists of 26 items under 5 domains. This study will analyze 4 of the domains, including the urinary, bowel, sexual, and hormonal domain. Each domain will be scaled, scored, and compared by arm.

    EPIC-26 assess participant function and bother on a qualitative scale which is then normalized on a scale of 0 to 100 (worst to best) to calculate individual domain scores.

  14. Change in IPSS Score

    Time frame: Baseline, 1 year after treatment

    The "International Prostate Symptom Score" (IPSS) is an eight-question questionnaire that will be administered as a health related quality of life measure for participants with prostate cancer. The IPSS score is reported on a scale of 0 to 35. Scores are broken down as: "Mild" (0 to 7 points), "Moderate" (8 to 19 points), and "Severe" (20 to 35 points). The change in IPSS score from baseline prior to treatment to one year after treatment will be measured.

  15. Change in IPSS Score

    Time frame: Baseline, 3 year after treatment

    The "International Prostate Symptom Score" (IPSS) is an eight-question questionnaire that will be administered as a health related quality of life measure for participants with prostate cancer. The IPSS score is reported on a scale of 0 to 35. Scores are broken down as: "Mild" (0 to 7 points), "Moderate" (8 to 19 points), and "Severe" (20 to 35 points). The change in IPSS score from baseline prior to treatment to three years after treatment will be measured.

  16. Skeletal-related events (SRE)

    Time frame: 5 years after treatment

    Time to the first skeletal-related event is defined as the time from randomization to the first new pathological bone fracture, spinal cord compression, tumor-related orthopedic surgery, and radiation therapy for bone pain. The SRE will be summarized in each arm and compared using Chi-square tests, as well as time-to-event analyses using cumulative incidence methods. The univariable generalized linear models (e.g., Poisson or negative binomial model) will be used to quantify the MDRT effect on the frequency of SRE.

Study contacts

Contact information is provided by the study sponsor or research team.

Angela Y Jia, MD, PhD

CONTACT

[email protected]

216-844-3262

Sponsors and collaborators

Lead sponsor

Case Comprehensive Cancer Center

Other

Collaborators

  • National Cancer Institute (NCI)
  • National Institutes of Health (NIH)

Registry information

Official study title

Metastasis-directed Radiotherapy (MDRT) for Men With De-novo Oligometastatic Prostate Cancer Treated With Long-term Androgen Deprivation Therapy in the STAMPEDE Trial (METANOVA)

Important dates

Study start
2024
Primary completion
2028
Study completion
2028
First posted
Nov 29, 2023
Registry last updated
Jul 20, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.